西妥昔单抗联合同期顺铂化疗加调强放疗治疗局部晚期鼻咽癌的疗效分析

目的探讨西妥昔单抗联合同期顺铂化疗加调强放疗治疗局部晚期鼻咽癌的安全性、疗效及不良反应。方法选取2009年1月-2012年12月该院收治的40例晚期鼻咽癌患：者作为观察对象，随机分为研究组和对照组，每组各20例。对照组采用同期顺铂化疗和调强放疗治疗，研究组在对照组基础上添加西妥昔单抗联合治疗。观察两组治疗效果及不良反应。结果经过7周规范治疗后，研究组治疗总有效率为90．00％，显著优于对照组70．00％，差异有统计学意义（Х^2=14．27，P〈0．05）：研究组骨髓抑制、消化道反应、皮肤干燥、发热、放射性咽喉炎等不良反应发生率均明显低于对照组，差异有统计学意义（P〈0．05）。结论西妥昔单抗联合同步化疗顺铂方案及三维适形调强放疗治疗局部晚期鼻咽癌，治疗效果优异，不良反应发生率低。患者容易耐受该治疗方案，值得临床推广应用。

Analysis on the Curative Effect of Cetuximab Combined with Concurrent Cisplatin Chemotherapy and Intensity Modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma

Objective To investigate the safety, efficacy and toxicity of cetuximab combined with concurrent cisplatin chemotherapy and intensity modulated radiation therapy for locally advanced nasopharyngeal carcinoma. Methods 40 cases of advanced nasopharyngeal carcinoma admitted in our hospital from January, 2009 to December, 2012 were selected as the study objects, and were randomly divided into study group and control group, eacb group had20 cases. The control group used concurrent cisplatin chemotherapy and intensity modulated radiation therapy, and the study group added cetuximab based on the treatment for the control group. The therapeutic effect and adverse reactions of two groups were observed. Results After 7 weeks of standard treatment, the total effective rate in the study group was 90.00%, obviously higher than 70.00% in the control group, the difference was significant （Х^2=14.27,P〈0.05）; the incidences of adverse reactions such as bone marrow suppression, digestive tract reaction, dry skin, fever, radiation laryngopharyngitis of the study group were significantly lower than those of the control group, the differences were statistically significant （P〈0.05）. Conclusion Cetuximab combined with concurrent cisplatin chemotherapy and intensity moddated radiation therapy has excellent treatment effect in treating locally advanced nasopharyngeal carcinoma with low incidence of adverse reactions, and it is easy to be tolerated by patients and worthy of clinical application.